Overexpression of miR‐216b: Prognostic and predictive value in acute myeloid leukemia

Abstract

Accumulating studies have shown that miR-216b acted as a tumor suppressor and was down-regulated in solid tumors. However, little studies revealed the role or clinical implication of miR-216b in blood cancers. Herein, we reported miR-216b expression and its clinical significance in patients with acute myeloid leukemia (AML). In the current study, we analyzed bone marrow (BM) miR-216b expression in 115 de novo AML patients examined by real-time quantitative PCR. Notably, BM miR-216b expression was significantly up-regulated in AML patients, and could serve as a potential biomarker distinguishing AML from controls. No significant correlations of BM miR-216 expression were found with sex, age, white blood cells, hemoglobin, platelets, BM blasts, French-American-British classifications, and karyotypes. Significantly, patients with high miR-216b expression tended to have a lower frequency of FLT3-ITD mutation and higher incidence of U2AF1 and IDH1/2 mutations. Moreover, complete remission (CR) rate and overall survival were negatively affected by BM miR-216b overexpression among cytogenetically normal AML (CN-AML). Cox regression analyses showed that high BM miR-216b expression may act as an independent risk factor in CN-AML patients. Among the follow-up patients, BM miR-216b level in CR phase was markedly lower than in diagnosis time, and was returned in relapse phase. Collectively, our findings indicated that miR-216b overexpression was a frequent event in de novo AML, and independently conferred a poor prognosis in CN-AML. Moreover, miR-216b expression was a valuable biomarker correlated with disease recurrence in AML.

Role of Circular RNA DLEU2 in Human Acute Myeloid Leukemia

“…Overexpression of miR-217 inhibited cellular proliferation and enhanced cell chemosensitivity to doxorubicin by the cell apoptosis pathway in AML cells (17). Some studies have clarified the potential roles of miRNAs as diagnostic and prognostic biomarkers in leukemia (18). For example, Li et al showed that increased expression of miR-181a or miR-181b was significantly associated with longer overall survival (OS) in AML patients (19).…”

Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia

“…These findings suggested that measuring miRNA may have potential advantages for predicting prognosis of AML compared to assessed gene mutations such as DMNT3A, FLT3-ITD, NPM1, and CEBPA. In published studies, univariate and multivariate analysis showed that miR-98, miR-99a, miR-340, miR-216b, and miR-34c had independent stronger prognostic impact on EFS and OS (P < 0.05) than gene mutations in FLT3-ITD, NPM1, DMNT3A, RUNX1, CEBPA, and TP53 [80,81,85,86].…”

“…Mounting studies have shown that miRNAs can be used to predict outcome in CN-AML. Zhang et al reported miR-216b overexpression as an independently poor prognostic factor for CN-AML and may provide a valuable biomarker associated with disease recurrence in AML [65]. In 224 patients with CN-AML, high miR-362-5p expression was associated with older age and shorter OS compared with low expressers [66].…”

RETRACTED ARTICLE: Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia

“…miRNAs have many properties of good AML prognostic biomarkers, such as wide presence in various tissues, highly conserved sequences, and easy and sensitive detection, as well as stability under extreme conditions [8]. Mounting studies have shown that miRNAs can be used to predict outcome in CN-AML.…”